The jump in prescription fills comes despite limited insurance coverage and high out-of-pocket costs for Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
Related Posts
From Nike to Intel, CEO departures at U.S. companies hit a record this year
CEO exits at U.S. public companies were a record in 2024 as they faced competitive and strategic challenges.
The CPI report Wednesday is expected to show progress on inflation has hit a wall
The consumer price index is expected to show a 2.7% 12-month inflation rate for November.
Why it’s so hard to find starter homes in the U.S.
Homes that are modest in size and price make up roughly 9% of new homes built in the U.S. That’s down sharply from decades earlier.